Top-News
Professionelle Dienstleistungen Schweiz

Relief Therapeutics SA Aktie

Aktie
WKN:  A3EFB5 ISIN:  CH1251125998 US-Symbol:  RLFTF
5,9248 €
-0,8221 €
-12,18%
6,45 $ 31.10.24
Handeln Depot/Watchlist
Aktienanzahl *
11,01 Mio.
Marktkapitalisierung *
74,67 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 28.06.2024

Relief Therapeutics SA News

29.10.24 - DGAP
Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE
Relief Therapeutics Holding SA / Key word(s): Miscellaneous Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE 29.10.2024 / 07:00 CET/CEST
25.10.24 - DGAP
Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents
Relief Therapeutics Holding SA / Key word(s): Study results Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents 25-Oct-2024 / 07:00 ...
21.10.24 - DGAP
Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
Relief Therapeutics Holding SA / Key word(s): Patent Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound ...
08.10.24 - DGAP
Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
Relief Therapeutics Holding SA / Key word(s): Study results Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa 08-...
04.10.24 - DGAP
Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria
Relief Therapeutics Holding SA / Key word(s): Study results Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-​of-Concept Clinical Study for Phenylketonuria 04-...
23.09.24 - DGAP
Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement
Relief Therapeutics Holding SA / Key word(s): Miscellaneous Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement 23-Sep-2024 / 07:00 CET/CEST ...
03.05.23 - DGAP
Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares
Relief Therapeutics Holding SA / Key word(s): Miscellaneous Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares 03.05.2023 / 07:00 ...
01.05.23 - DGAP
Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA™ Commercial Launch Progressing Ahead of Schedule
Relief Therapeutics Holding SA / Key word(s): Market Launch Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA™ Commercial Launch Progressing Ahead of ...
28.04.23 - DGAP
Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders
Relief Therapeutics Holding SA / Key word(s): AGMEGM Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders 28.04.2023 / 19:00 CET/CEST
17.04.23 - DGAP
Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100
Relief Therapeutics Holding SA / Key word(s): Research Update Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-...
14.04.23 - DGAP
Relief Therapeutics Announces Full Year 2022 Financial Results and Provides Corporate Update
Relief Therapeutics Holding SA / Key word(s): Annual Results Relief Therapeutics Announces Full Year 2022 Financial Results and Provides Corporate Update 14-Apr-2023 / 07:00 ...
05.04.23 - DGAP
Relief Therapeutics Announces Executive Leadership Team Change
Relief Therapeutics Holding SA / Key word(s): Personnel Relief Therapeutics Announces Executive Leadership Team Change 05-Apr-2023 / 07:00 CET/CEST Release of an ad hoc ...
04.04.23 - DGAP
Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders
Relief Therapeutics Holding SA / Key word(s): AGMEGM Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders 04-Apr-2023 / 07:00 CET/CEST ...
03.04.23 - DGAP
Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory Board
Relief Therapeutics Holding SA / Key word(s): Personnel Relief Therapeutics Appoints World-​Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory ...
22.03.23 - DGAP
Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023
Relief Therapeutics Holding SA / Key word(s): Study results Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented ...
17.03.23 - DGAP
Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual Meeting
Relief Therapeutics Holding SA / Key word(s): Study results Relief Therapeutics to Present Pre-​Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society ...
16.03.23 - DGAP
Relief Therapeutics Announces Availability of New PKU GOLIKE BARs in Europe
Relief Therapeutics Holding SA / Key word(s): Market Launch Relief Therapeutics Announces Availability of New PKU GOLIKE BARs in Europe 16.03.2023 / 07:00 CET/CEST
15.03.23 - DGAP
Relief Therapeutics Provides Update From Collaboration Partner on OLPRUVA™ 
Relief Therapeutics Holding SA / Key word(s): Market Launch Relief Therapeutics Provides Update From Collaboration Partner on OLPRUVA™  15-March-2023 / 07:00 CET/CEST ...
28.02.23 - DGAP
Relief Therapeutics Recognizes Rare Disease Day and Announces U.S. Availability of New PKU GOLIKE Bars
Relief Therapeutics Holding SA / Key word(s): Market Launch Relief Therapeutics Recognizes Rare Disease Day and Announces U.S. Availability of New PKU GOLIKE Bars ...
14.02.23 - DGAP
Relief Therapeutics Announces Enrollment of First Three Patients in Proof-of-Concept Clinical Trial of RLF-TD011 for the Treatment of Epidermolysis Bullosa
Relief Therapeutics Holding SA / Key word(s): Study Relief Therapeutics Announces Enrollment of First Three Patients in Proof-​of-Concept Clinical Trial of RLF-TD011 for the ...

Newssuche

Videos

newspaper
31.10.24 -11,51%
Technical Trading: 83% Trefferquote für diesen Trade
Nasdaq Long Typ: Turbo Open End WKN: VM433C Hebel: 5 Laufzeit: OpenEnd Einstieg: Market ... Mehr »
Anzeige

Aktie im Fokus

1.000 % Chance
Desert Gold Ventures Inc.
0,0465 €
-15,5%
Desert Gold Ventures Inc. Chart
Neuer Gold Rekord bei knapp 2.800 USD und Übernahme-Zirkus!
Mehr zur Aktie »